Ursodeoxycholic acid

SKU: orb1310372

Description

Ursodeoxycholic acid (UDCA) is a research compound known for its potent inhibition of the hepatic fatty acid transporter FATP5. It is widely used in studies investigating cholesterol metabolism, gallstone dissolution, and liver diseases, with applications in both in vitro and in vivo experimental models.

Research Area

Metabolism Research, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 128-13-2
• MW: 392.57
• Purity: 99.91% (May vary between batches)
• Formula: C₂₄H₄₀O₄
• SMILES: C[C@@]12[C@]([C@]3([C@@]([C@]4(C)[C@](C[C@@H]3O)(C[C@H](O)CC4)[H])(CC1)[H])[H])(CC[C@@]2([C@@H](CCC(O)=O)C)[H])[H]
• Target: GPCR19,Potassium Channel,FXR,Angiotensin-converting Enzyme (ACE),Endogenous Metabolite
• Solubility: H2O:< 1 mg/mL (insoluble or slightly soluble);Ethanol:73 mg/mL (185.95 mM);DMSO:255 mg/mL (649.57 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (12.74 mM)

Bioactivity

• Target IC50:
  CHO cells:36.4 μM (EC50)|A549 cells:> 200 μM|GBM:> 50 μM
• In Vivo:
  METHODS: To study the effect of Ursodeoxycholic acid on body weight, Ursodeoxycholic acid (50, 150, and 450 mg/kg) was administered orally to mice for 21 days. RESULTS: Significant weight loss was observed within a week in the groups of mice receiving 50 and 450 mg/kg doses. At the 50 mg/kg dose, this weight loss persisted throughout the experiment. At a dose of 450 mg/kg, weight loss was initially observed during the first and third weeks of Ursodeoxycholic acid administration. At the 150 mg/kg dose, there was no significant difference in body weight compared to untreated mice.
• In Vitro:
  METHODS: Ovarian cancer cell line A2780 and cisplatin-resistant cell line A2780 were treated with Ursodeoxycholic acid (300 nM) for 4 hours, and the cell growth inhibition was detected by MTT assay. RESULTS: Ursodeoxycholic acid inhibited the growth of ovarian cancer A2780 cells (IC50=300 nM) and cisplatin-resistant A2780 cells (IC50=300 nM). METHODS: Colorectal cancer cells SW620 and HCT116 were treated with Ursodeoxycholic acid (0, 0.00625, 0.0125, 0.025, 0.05, 0.1 mg/mL) for 24 hours, and MTT assay was used to detect the inhibitory effect of ursodeoxycholic acid on cell growth. RESULTS: Ursodeoxycholic acid inhibited the growth of colorectal cancer cells SW620 (IC50=0.02 mg/mL) and HCT116 (IC50=0.016 mg/mL).

Storage & Handling

• Storage: keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Bile salt export pump, FXR, G protein-coupled Bile Acid Receptor 1, G-protein coupled receptor 19, GPCR19, GPBAR1, EndogenousMetabolite, Endogenous Metabolite, Inhibitor, gastrointestinal diseases, hepatic, oral, inhibit, intestinal barrier integrity, NR1H4, lipid metabolism, PotassiumChannel, Potassium Channel, secondary bile acid, UDCA, Ursodeoxycholate, Ursodiol, Ursodeoxycholic acid, UDCS, TGR5

Compound Identifiers

PubChem CID

5645